RBM15

Across TCGA pan-cancer cohorts, RBM15 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBM15 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM15 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM15 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where RBM15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.757	0.946	.006	57	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
CCRCC	DFS	Median	III,IV	0.774	0.207	.047	2	view →
GBM	OS	Median	All	0.464	0.296	.030	2	view →
LUAD	OS	Median	II,III,IV	0.891	0.455	.035	2	view →
LSCC	DFS	Median	All	0.972	0.907	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBM15–HNSC (OS)

Open the HNSC breakdown →